PAHC
Price
$30.66
Change
+$0.10 (+0.33%)
Updated
Aug 15, 04:59 PM (EDT)
Capitalization
1.24B
12 days until earnings call
ZTS
Price
$154.10
Change
+$1.04 (+0.68%)
Updated
Aug 15, 04:59 PM (EDT)
Capitalization
67.83B
76 days until earnings call
Interact to see
Advertisement

PAHC vs ZTS

Header iconPAHC vs ZTS Comparison
Open Charts PAHC vs ZTSBanner chart's image
Phibro Animal Health
Price$30.66
Change+$0.10 (+0.33%)
Volume$4.75K
Capitalization1.24B
ZOETIS
Price$154.10
Change+$1.04 (+0.68%)
Volume$36.41K
Capitalization67.83B
PAHC vs ZTS Comparison Chart in %
Loading...
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PAHC vs. ZTS commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PAHC is a Hold and ZTS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (PAHC: $30.57 vs. ZTS: $153.06)
Brand notoriety: PAHC: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: PAHC: 69% vs. ZTS: 80%
Market capitalization -- PAHC: $1.24B vs. ZTS: $67.83B
PAHC [@Pharmaceuticals: Generic] is valued at $1.24B. ZTS’s [@Pharmaceuticals: Generic] market capitalization is $67.83B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.83B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.72B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PAHC’s FA Score shows that 1 FA rating(s) are green whileZTS’s FA Score has 1 green FA rating(s).

  • PAHC’s FA Score: 1 green, 4 red.
  • ZTS’s FA Score: 1 green, 4 red.
According to our system of comparison, PAHC is a better buy in the long-term than ZTS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PAHC’s TA Score shows that 4 TA indicator(s) are bullish while ZTS’s TA Score has 6 bullish TA indicator(s).

  • PAHC’s TA Score: 4 bullish, 5 bearish.
  • ZTS’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, ZTS is a better buy in the short-term than PAHC.

Price Growth

PAHC (@Pharmaceuticals: Generic) experienced а +11.86% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was +3.25% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

PAHC is expected to report earnings on Aug 27, 2025.

ZTS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($67.8B) has a higher market cap than PAHC($1.24B). PAHC has higher P/E ratio than ZTS: PAHC (39.19) vs ZTS (26.34). PAHC YTD gains are higher at: 47.026 vs. ZTS (-5.140). PAHC has less debt than ZTS: PAHC (770M) vs ZTS (6.75B).
PAHCZTSPAHC / ZTS
Capitalization1.24B67.8B2%
EBITDA123MN/A-
Gain YTD47.026-5.140-915%
P/E Ratio39.1926.34149%
Revenue1.19BN/A-
Total Cash70.4MN/A-
Total Debt770M6.75B11%
FUNDAMENTALS RATINGS
PAHC vs ZTS: Fundamental Ratings
PAHC
ZTS
OUTLOOK RATING
1..100
549
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
35
Fair valued
PROFIT vs RISK RATING
1..100
6387
SMR RATING
1..100
6319
PRICE GROWTH RATING
1..100
4261
P/E GROWTH RATING
1..100
8384
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (27) in the Pharmaceuticals Major industry is in the same range as ZTS (35) in the Pharmaceuticals Generic industry. This means that PAHC’s stock grew similarly to ZTS’s over the last 12 months.

PAHC's Profit vs Risk Rating (63) in the Pharmaceuticals Major industry is in the same range as ZTS (87) in the Pharmaceuticals Generic industry. This means that PAHC’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's SMR Rating (19) in the Pharmaceuticals Generic industry is somewhat better than the same rating for PAHC (63) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew somewhat faster than PAHC’s over the last 12 months.

PAHC's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as ZTS (61) in the Pharmaceuticals Generic industry. This means that PAHC’s stock grew similarly to ZTS’s over the last 12 months.

PAHC's P/E Growth Rating (83) in the Pharmaceuticals Major industry is in the same range as ZTS (84) in the Pharmaceuticals Generic industry. This means that PAHC’s stock grew similarly to ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PAHCZTS
RSI
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
53%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
55%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
60%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
59%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
58%
Advances
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 2 days ago
56%
Declines
ODDS (%)
Bearish Trend 10 days ago
71%
Bearish Trend 16 days ago
56%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
69%
Aroon
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
PAHC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MEGI14.460.16
+1.12%
NYLI CBRE Global Infrastructure Megatrends Term Fund
NPV11.120.07
+0.63%
Nuveen Virginia Quality Municipal Income Fund
QCON48.49-0.12
-0.26%
American Century Quality Cnvtbl Scts ETF
RMOP24.17-0.08
-0.33%
Rockefeller Opportunistic Muncpl Bd ETF
VBK285.61-4.09
-1.41%
Vanguard Small-Cap Growth ETF

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with AMRX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
-1.26%
AMRX - PAHC
47%
Loosely correlated
-0.11%
ZTS - PAHC
43%
Loosely correlated
+0.41%
PBH - PAHC
41%
Loosely correlated
-2.75%
ELAN - PAHC
40%
Loosely correlated
+1.07%
VTRS - PAHC
39%
Loosely correlated
+2.69%
More

ZTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
+0.41%
ELAN - ZTS
46%
Loosely correlated
+1.07%
VTRS - ZTS
45%
Loosely correlated
+2.69%
PAHC - ZTS
44%
Loosely correlated
-1.26%
HLN - ZTS
38%
Loosely correlated
+0.10%
AMRX - ZTS
38%
Loosely correlated
-0.11%
More